BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Inflammatory disorder, Hypothalamus, Neocentromeres, Rapamycin, rs6983267, PPARA)
Bookmark Forward

QuickView for B-Raf protein (gene)


Body Atlas

Most Correlated Tissues

  1. Cerebellar hemisphere
  2. Cerebellar vermis
  3. Cerebellum
  4. Thalamus lateral nuclei
  5. Prefrontal cortex
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Cardio-facio-cutaneous syndrome
  2. Lentigo
  3. Noonan's syndrome
  4. Hyperpigmentation of skin
  5. Turner syndrome
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Oxyphenisatin Acetate
  2. phensuximide
  3. Maneb
  4. 4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo(2,3-d)-pyrimidine-5-carboxamide
  5. Nordihydroguaiaretic Acid
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. TLX3
  2. CBX2
  3. AKT3
  4. DCAF1
  5. ATP5F1B
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
  2. Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.
  3. Computational analysis of natural product B-Raf inhibitors.
  4. Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.
  5. A novel BRAF::PTPRN2 fusion in meningioma: a case report.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
  2. Study of IK-595 in RAS- or RAF-altered Advanced Tumors
  3. Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Color…
  4. Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
  5. Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.